Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Apr 1, 2008 → Nov 1, 2010
NCT ID
NCT00664534About Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture) is a approved stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00664534. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00664534 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2